Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Each diabetic patients in the control group, in addition to routine type 2 diabetic patients drugs, will receive daily 3 placebo capsules at 3 in the morning, noon and night . Inter
Placebo
Treatment - Drugs
Each diabetic patients in the control group, in addition to routine type 2 diabetic patients drugs, will receive daily 3 placebo capsules at 3 in the morning, noon and night .
Each diabetes patient in the intervention group, in addition to routines medication of type 2 diabetic, will receive the daily 3 capsules of 400 mg, containing the extract of the fruit of Berberis vu
Sponsors
Shahrekord University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: diagnosis of type 2 diabetes patients; age between 30 to 60 years; fasting blood sugar =126mg / dl; venous plasma glucose 2 hours after ingestion of 75 g glucose =200mg / dl; not receiving insulin; HBA1C from 7 to 8.5 percent; duration of diabetes diagnosis be less than 10 years; only using the blood glucose lowering drugs. Exclusion criteria: age less than 30 and more than 60 years; insulin taking; smoking; chronic cardiovascular disease; chronic renal disease; triglycerides more than 500 mg / d; pregnancy; use of anticoagulant drugs (except aspirin); chronic liver disease other than fatty liver; advanced diabetic retinopathy; kidney failure; heart failure; hemorrhagic stroke; high and low work hypothyroidism.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fast blood suger. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and blood glucose measurement.;HbA1C. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;HDL-C. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;LDL-C. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;TG. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;Total Chol. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;VLDL. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Calculation.;BUN. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;Cratinine. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;AST. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;ALT. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Blood sampling and measurement of blood.;Patient weight. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Using the scale.;Length of patient. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Using a tape measure fixed on the wall (on the scale).;BMI. Timepoint: Baseline and after 2 months (end of the study). Method of measurement: Calculation. | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL-C. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;LDL-C. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;Triglycerides. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;Total cholesterol. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;VLDL. Timepoint: Baseline and end of the study. Method of measurement: Computing.;BUN. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;Cratinine. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;AST. Timepoint: Baseline and end of study. Method of measurement: Blood and serum isolated from blood.;ALT. Timepoint: Baseline and end of the study. Method of measurement: Blood and serum isolated from blood.;Weight. Timepoint: Baseline and end of the study. Method of measurement: Using the same and standardized scale.;BMI. Timepoint: Baseline and end of the study. Method of measurement: Computing. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Rahimi Madiseh
Shahrekord University Of Medical Sciences
Outcome results
None listed